$FUSN News
Last published 2y ago
- 2y agoFUSNAcquisition of Fusion Pharmaceuticals CompletedPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced...
- 2y agoFUSNFusion Pharmaceuticals Receives Final Court Order Approving ArrangementPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoFUSNFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoAZN-GBBMYLLYNVS+4This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&ACNBCTargeted radiopharmaceuticals, which deliver radiation directly into tumors, has caught the eye of big pharma.
- 2y agoNOVO.B-DKAZN-GBLLYAZN+2AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicinesCNBCPharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.
- 2y agoAGSCVLYDRQFUSNKuehn Law Encourages AGS, FUSN, CVLY, and DRQ Investors to Contact Law FirmGlobeNewswireNEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoFUSNFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoAZNFUSNGOOGLBRK.AAstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demandCNBCPharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined.
- 2y agoFUSNFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoHCPIPSLCAFUSNKuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoFUSNFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as...
- 2y agoCHXDRQFUSNHMSTKuehn Law Encourages HMST, CHX, FUSN, and DRQ Investors to Contact Law FirmGlobeNewswireNEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoFUSNFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024PR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoDRQEVBGFREEFUSNKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoFUSNFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program UpdatesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat CancerPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
- 2y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual MeetingPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals to Present at Upcoming March Investor ConferencesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted RadiotherapyPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNFusion Pharmaceuticals Announces Clinical Program and Manufacturing UpdatesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 2y agoFUSNBWXTFusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical CollaborationPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the...
- 2y agoBWXTFUSNBWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator TechnologyBusiness WireAgreement Furthers BWXT Medical's Position as a Global Leader in Actinium Supply
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 3y agoFUSNFusion Pharmaceuticals to Present at Upcoming Investor ConferencesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 3y agoFUSNFusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program UpdatesPR NewswireFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
- 3y agoAZNFUSNFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing CancersPR NewswireData presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse models FPI-2068,
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, Sept. 6, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals to Present at Upcoming September Investor ConferencesPR NewswireHAMILTON, ON and BOSTON, Sept. 5, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, Aug. 9, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program UpdatesPR NewswireFPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, July 6, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1RPR NewswirePreliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is
- 3y agoFUSNFusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation SummitPR NewswireHAMILTON, ON and BOSTON, June 16, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, June 7, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals to Present at the Jefferies Healthcare ConferencePR NewswireHAMILTON, ON and BOSTON, May 31, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program UpdatesPR NewswireFPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- 3y agoFUSNFusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayPR NewswireHAMILTON, ON and BOSTON, May 9, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for CancerPR NewswireFacility is on track to be fully operational in 2024 HAMILTON, ON, May 2, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation
- 3y agoFUSNFusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor ConferencePR NewswireHAMILTON, ON and BOSTON, April 20, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual MeetingPR NewswireFPI-2059 induces tumor growth inhibition in colorectal tumor model TEM-1 and EGFRvIII demonstrate potential as TAT targets HAMILTON, ON and BOSTON, April 19, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a
- 3y agoAZNFUSNFusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha TherapyPR NewswireFPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells HAMILTON, ON and BOSTON, April 12, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, April 5, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1PR NewswireHAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines,
- 3y agoFUSNFusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program UpdatesPR NewswireCompany recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2
- 3y agoFUSNFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireHAMILTON, ON and BOSTON, March 8, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare ConferencePR NewswireHAMILTON, ON and BOSTON, March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today
- 3y agoFUSNFusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate CancerPR NewswireAcquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million private placement